John Maher | Chief Scientific Officer
Leucid Bio

John Maher, Chief Scientific Officer, Leucid Bio

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.

Appearances:



Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 11:40

Plenary Round Table Discussion Session: Process Development & Manufacturing Focus

Table 6. Clinical development of Immunotherapy & cell therapy

Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 14:30

Panel Discussion: How can clinical challenges be overcome to enable CAR-T and immunotherapy to help more patients?

Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 17:30

Intra tumour application of CAR-T therapy to treat solid head and neck cancer

  •          Robust manufacture of T4 immunotherapy can be achieved from lymphopenic patients with advanced head and neck cancer using a blood draw
  •          Intratumoural T4 immunotherapy of head and neck cancer has proven safe to date, at doses of up to 100 million CAR T-cells
  •          Cautious dose escalation will proceed in order to define the maximum tolerated dose of this immunotherapy

back to speakers

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com